Northern Trust Corp Biovie Inc. Transaction History

Northern Trust Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.4 - $0.56 $9,710 - $13,595	-24,277 Reduced 21.03%	91,181 $36,000
Q1 2024 May 14, 2024	BUY	$0.53 - $1.89 $3,464 - $12,353	6,536 Added 6.0%	115,458 $61,000
Q4 2023 Feb 13, 2024	BUY	$1.22 - $5.24 $82,877 - $355,963	67,932 Added 165.73%	108,922 $137,000
Q3 2023 Nov 13, 2023	SELL	$2.75 - $5.17 $6,066 - $11,405	-2,206 Reduced 5.11%	40,990 $139,000
Q2 2023 Aug 11, 2023	BUY	$4.09 - $8.29 $94,638 - $191,822	23,139 Added 115.37%	43,196 $186,000
Q1 2023 May 15, 2023	BUY	$4.89 - $10.53 $36,362 - $78,301	7,436 Added 58.92%	20,057 $162,000
Q4 2022 Feb 13, 2023	BUY	$3.86 - $42.0 $48,717 - $530,082	12,621 New	12,621 $98,000

340K

Ticker BIVI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,165,300
Market Cap $64.3M
Description
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial ...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.